AAAAAA
Results:
1-24
|
Results: 24
Authors:
KORTT MA
LANGLEY PC
COX ER
Citation: Ma. Kortt et al., A REVIEW OF COST-OF-ILLNESS STUDIES ON OBESITY, Clinical therapeutics, 20(4), 1998, pp. 772-779
Authors:
HAWKINS DW
LANGLEY PC
KRUEGER KP
Citation: Dw. Hawkins et al., A PHARMACOECONOMIC ASSESSMENT OF ENOXAPARIN AND WARFARIN AS PROPHYLAXIS FOR DEEP-VEIN THROMBOSIS IN PATIENTS UNDERGOING KNEE REPLACEMENT SURGERY, Clinical therapeutics, 20(1), 1998, pp. 182-195
Authors:
DAVIES A
LANGLEY PC
KEKS NA
CATTS SV
LAMBERT T
SCHWEITZER I
Citation: A. Davies et al., RISPERIDONE VERSUS HALOPERIDOL - II - COST-EFFECTIVENESS, Clinical therapeutics, 20(1), 1998, pp. 196-213
Authors:
LANGLEY PC
Citation: Pc. Langley, COST-EFFECTIVENESS AND ALLOCATION OF THERAPIES IN A TREATING POPULATION - REPLY, PharmacoEconomics, 11(6), 1997, pp. 606-608
Authors:
LANGLEY PC
COONS SJ
Citation: Pc. Langley et Sj. Coons, PERIPHERAL VASCULAR DISORDERS - A PHARMACOECONOMIC AND QUALITY-OF-LIFE REVIEW, PharmacoEconomics, 11(3), 1997, pp. 225-236
Authors:
LANGLEY PC
MARTIN RE
Citation: Pc. Langley et Re. Martin, MANAGED CARE GUIDELINES FOR THE ECONOMIC-EVALUATION OF PHARMACEUTICALS, American journal of managed care, 3(7), 1997, pp. 1013-1021
Authors:
HAWKINS DW
LANGLEY PC
KRUEGER KP
Citation: Dw. Hawkins et al., PHARMACOECONOMIC MODEL OF ENOXAPARIN VERSUS HEPARIN FOR PREVENTION OFDEEP-VEIN THROMBOSIS AFTER TOTAL HIP-REPLACEMENT, American journal of health-system pharmacy, 54(10), 1997, pp. 1185-1190
Authors:
LANGLEY PC
Citation: Pc. Langley, IMPROVING HEALTH-CARE OUTCOMES THROUGH REALLOCATION OF HEALTH-CARE EXPENDITURES, Clinical therapeutics, 19(5), 1997, pp. 1092-1100
Authors:
LANGLEY PC
Citation: Pc. Langley, THE FUTURE OF PHARMACOECONOMICS - A COMMENTARY, Clinical therapeutics, 19(4), 1997, pp. 762-769
Authors:
LANGLEY PC
BHATTACHARYYA SK
Citation: Pc. Langley et Sk. Bhattacharyya, TREATMENT COSTS, EQUILIBRIUM, AND THE ALLOCATION OF PATIENTS TO THERAPY ALTERNATIVES, Clinical therapeutics, 19(4), 1997, pp. 830-836
Authors:
LANGLEY PC
Citation: Pc. Langley, THE NOVEMBER 1995 REVISED AUSTRALIAN GUIDELINES FOR THE ECONOMIC-EVALUATION OF PHARMACEUTICALS, PharmacoEconomics, 9(4), 1996, pp. 341-352
Authors:
JOHNSON ES
SULLIVAN SD
MOZAFFARI E
LANGLEY PC
BODSWORTH NJ
Citation: Es. Johnson et al., A UTILITY-ASSESSMENT OF ORAL AND INTRAVENOUS GANCICLOVIR FOR THE MAINTENANCE TREATMENT OF AIDS-RELATED CYTOMEGALOVIRUS RETINITIS, PharmacoEconomics, 10(6), 1996, pp. 623-629
Authors:
LANGLEY PC
Citation: Pc. Langley, COST-EFFECTIVENESS AND THE ALLOCATION OF THERAPIES IN A TREATING POPULATION, PharmacoEconomics, 10(1), 1996, pp. 93-98
Authors:
ARMSTRONG EP
LANGLEY PC
Citation: Ep. Armstrong et Pc. Langley, DISEASE MANAGEMENT PROGRAMS (VOL 53, PG 53, 1996), American journal of health-system pharmacy, 53(3), 1996, pp. 325-325
Authors:
ARMSTRONG EP
LANGLEY PC
Citation: Ep. Armstrong et Pc. Langley, DISEASE MANAGEMENT PROGRAMS, American journal of health-system pharmacy, 53(1), 1996, pp. 53-58
Authors:
LANGLEY PC
Citation: Pc. Langley, ASSESSING THE INPUT COSTS OF DISEASE MANAGEMENT PROGRAMS, Clinical therapeutics, 18(6), 1996, pp. 1334-1340
Authors:
HARRISON DL
DRAUGALIS JR
SLACK MK
LANGLEY PC
Citation: Dl. Harrison et al., COST-EFFECTIVENESS OF REGIONAL POISON CONTROL CENTERS, Archives of internal medicine, 156(22), 1996, pp. 2601-2608
Authors:
LANGLEY PC
Citation: Pc. Langley, PHARMACOECONOMICS AND THE QUALITY OF DECISION-MAKING BY PHARMACY AND THERAPEUTICS COMMITTEES, American journal of health-system pharmacy, 52, 1995, pp. 24-26
Authors:
LANGLEY PC
Citation: Pc. Langley, SUBSTANTIATION IN PHARMACOECONOMIC EVALUATIONS - COMMENT, The Annals of pharmacotherapy, 29(9), 1995, pp. 942-943
Authors:
LANGLEY PC
Citation: Pc. Langley, COST-EFFECTIVENESS PROFILES WITH AN EXPANDING TREATMENT POPULATION, Clinical therapeutics, 17(6), 1995, pp. 1207-1212
Authors:
LANGLEY PC
Citation: Pc. Langley, THERAPY EVALUATION, PATIENT DISTRIBUTION, AND COST-OUTCOMES RATIOS, Clinical therapeutics, 17(2), 1995, pp. 341-347
Authors:
ORTMEIER BG
SAUER KA
LANGLEY PC
BEALMEAR BK
Citation: Bg. Ortmeier et al., A COST-BENEFIT-ANALYSIS OF 4 HORMONAL CONTRACEPTIVE METHODS, Clinical therapeutics, 16(4), 1994, pp. 707-713
Authors:
LANGLEY PC
Citation: Pc. Langley, OUTCOMES RESEARCH AND MODELING THERAPEUTIC INTERVENTIONS FOR ECONOMICEVALUATIONS, Clinical therapeutics, 16(3), 1994, pp. 538-552
Authors:
LANGLEY PC
Citation: Pc. Langley, THE ROLE OF PHARMACOECONOMIC GUIDELINES FOR FORMULARY APPROVAL - THE AUSTRALIAN EXPERIENCE, Clinical therapeutics, 15(6), 1993, pp. 1154-1176
Risultati:
1-24
|